KC
DNA icon

Kingfisher Capital’s Ginkgo Bioworks DNA Stock Holding History

Kingfisher Capital’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-625
Closed -$78K – 170
2022
Q3 		$78K Buy
625
+62
+11% +$7.39K 0.02% 170
2022
Q2 		$54K Buy
+563
New +$68.7K 0.02% 165

Other funds holding DNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

Kingfisher Capital's DNA Position: Q4 2022 in Review

Kingfisher Capital sold out of Ginkgo Bioworks (DNA) in Q4 2022, closing a stake of 625 shares — an estimated $78K sold.

Kingfisher Capital first reported a position in DNA in Q2 2022 and held it in 2 quarters. The position peaked at $78K in Q3 2022. 320 funds tracked by Wall St. Rank hold DNA as of Q4 2022.

  • Kingfisher Capital reported no remaining Ginkgo Bioworks position as of Q4 2022 after selling out during the quarter.
  • Kingfisher Capital sold 625 Ginkgo Bioworks shares in Q4 2022, an estimated $78K.
  • Kingfisher Capital first reported a position in Ginkgo Bioworks in Q2 2022 and held it in 2 quarters.
  • Kingfisher Capital's Ginkgo Bioworks position peaked at $78K in Q3 2022.
  • 320 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2022.

Based on Kingfisher Capital's 13F filing for Q4 2022, filed 19 Jan 2023.